Medicare Enrolled
Dr. Edsel Hesita, M.D.
Medical Oncology · San Antonio, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Hesita from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Hesita?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Hesita
Dr. Edsel Hesita is a medical oncology specialist in San Antonio, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Hesita performed 30,408 Medicare services across 2,786 unique beneficiaries.
Between the years covered by Open Payments, Dr. Hesita received a total of $2,178 from 31 pharmaceutical and/or device companies across 71 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Hesita is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 30% volume in TX
$2,178 industry payments
Medicare Practice Summary
Medicare Utilization ↗30,408
Medicare services
Top 30% in TX for medical oncology
2,786
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,600 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
16,200 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
6,150 | $0 | $5 |
| Injection, granisetron hydrochloride, 100 mcg | 1,060 | $0 | $24 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
804 | $0 | $1 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
678 | $8 | $36 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
651 | $8 | $20 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
513 | $10 | $64 |
| Flow cytometry, additional marker An additional marker is tested during a flow cytometry procedure to analyze DNA or cells. This step adds specific data points to the initial analysis. |
495 | $18 | $180 |
| Anti-nausea injection (Aloxi/palonosetron) | 450 | $1 | $114 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
400 | $59 | $250 |
| Immunoglobulin level test A blood test that measures the level of gammaglobulins, which are immune system proteins. |
282 | $9 | $56 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
275 | $21 | $157 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
210 | $95 | $707 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
205 | $90 | $368 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
176 | $10 | $96 |
| Immunoglobulin light chain measurement A blood test that measures the levels of immunoglobulin light chains, which are proteins produced by plasma cells. |
170 | $17 | $60 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
149 | $44 | $313 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
135 | $112 | $565 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
134 | $7 | $431 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
109 | $13 | $60 |
| Iron level test | 109 | $6 | $27 |
| Iron binding capacity test A blood test that measures the amount of iron in the blood and the blood's ability to bind and transport iron. |
109 | $9 | $35 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
98 | $52 | $211 |
| Beta-2 microglobulin level test A blood test that measures the level of beta-2 microglobulin, a protein produced by cells in the body. |
82 | $16 | $96 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
71 | $21 | $161 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
58 | $59 | $247 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
58 | $1 | $7 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
52 | $81 | $357 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 49 | $20 | $128 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
45 | $6 | $31 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
41 | $47 | $344 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
40 | $97 | $470 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
36 | $1 | $8 |
| Manual urinalysis with microscopic examination A urine test performed manually without automated equipment. The sample is examined under a microscope to check for abnormalities. |
33 | $4 | $26 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
27 | $18 | $114 |
| Serum protein measurement A blood test that measures the total amount of protein in the serum. It helps evaluate overall health and nutritional status. |
26 | $11 | $99 |
| Serum immunofixation test A laboratory test that analyzes a blood serum sample to identify specific abnormal proteins. The procedure uses an immunologic technique to detect and characterize these proteins. |
26 | $22 | $160 |
| Manual white blood cell count A laboratory test that involves examining a sample under a microscope to manually count the number of white blood cells present. |
25 | $4 | $22 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
25 | $6 | $34 |
| Prothrombin time test (blood clotting) A laboratory test that measures how long it takes for blood to clot. This procedure evaluates the body's coagulation process. |
22 | $4 | $30 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
21 | $19 | $99 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 21 | $86 | $657 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
21 | $2 | $19 |
| Flow cytometry DNA or cell analysis, first marker A laboratory test that uses a laser to analyze cells or DNA by detecting a specific marker on the cell surface or within the cell. |
20 | $56 | $298 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
17 | $1,050 | $4,802 |
| Vitamin B-12 level test A blood test that measures the amount of vitamin B-12 in your body. |
16 | $15 | $76 |
| Folic acid level test A blood test that measures the amount of folic acid in the serum. |
14 | $14 | $73 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
2.3% high complexity
82.9% medium
14.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,178
Total received (2018-2024)
Avg $311/year across 7 years
Bottom 40% in TX for medical oncology
31
Companies
71
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,101 (96.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$78 (3.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$382
2023
$612
2022
$261
2021
$152
2020
$97
2019
$420
2018
$254
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Myriad Genetic Laboratories, Inc.
$533
E.R. Squibb & Sons, L.L.C.
$201
PFIZER INC.
$182
Janssen Biotech, Inc.
$147
Genmab U.S., Inc.
$125
ImmunoGen, Inc.
$125
AstraZeneca Pharmaceuticals LP
$101
Amgen Inc.
$97
ABBVIE INC.
$70
Lilly USA, LLC
$60
Bayer HealthCare Pharmaceuticals Inc.
$52
Genentech USA, Inc.
$52
Kite Pharma, Inc.
$46
Novartis Pharmaceuticals Corporation
$35
Celgene Corporation
$34
Pharmacyclics LLC, An AbbVie Company
$34
Merck Sharp & Dohme Corporation
$29
Janssen Pharmaceuticals, Inc
$27
Exelixis Inc.
$26
Seagen Inc.
$21
Kyowa Kirin, Inc.
$20
Daiichi Sankyo Inc.
$20
Merck Sharp & Dohme LLC
$18
Ipsen Biopharmaceuticals, Inc
$18
Sobi, Inc
$18
Regeneron Healthcare Solutions, Inc.
$17
Taiho Oncology, Inc.
$16
Astellas Pharma US Inc
$15
Helsinn Therapeutics (U.S.), Inc.
$14
Array BioPharma Inc.
$12
Gilead Sciences, Inc.
$12
Top 3 companies account for 42.0% of total payments
Associated products mentioned in payments ›
AKYNZEO · ALIMTA · Abraxane · Braftovi · CALQUENCE · CHANTIX · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · ELIQUIS · EMPLICITI · ENHERTU · ERLEADA · Elahere · Epkinly · GAZYVA · INJECTAFER · Imbruvica · KEYTRUDA · Kyprolis · LIBTAYO · LINZESS · LONSURF · LYNPARZA · MYRISK · Neulasta · Nplate · OPDIVO · PADCEV · POTELIGEO · PRECISETUMOR · PROMACTA · REBLOZYL · SOMATULINE DEPOT · Stivarga · TECENTRIQ · TIVDAK · VERZENIO · VIBERZI · Vitrakvi · XARELTO · Yescarta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $7 per 100 Medicare services performed
Geographic Context
Medical oncologists within 10 mi
37
Per 100K population
1.8
County median income
$70,571
Nearest hospital
WESTOVER HILLS BAPTIST HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Hesita is a mixed practice specialist, with above-average Medicare volume (top 30% in TX), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Hesita experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Hesita performed 16,200 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Hesita receive payments from pharmaceutical companies?
Yes. Dr. Hesita received a total of $2,178 from 31 companies across 71 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Hesita's costs compare to other medical oncologists in San Antonio?
Dr. Hesita's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Hesita) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in San Antonio
Browse medical oncologists in San Antonio ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in TX
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in TX
Which TX medical oncologists receive the most from drug and device companies.
By company
Myriad Genetic Laboratories, Inc. Payments to Doctors
See all physicians who received payments from Myriad Genetic Laboratories, Inc.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology